Literature DB >> 9322527

Contribution of Fas ligand to T cell-mediated hepatic injury in mice.

K Seino1, N Kayagaki, K Takeda, K Fukao, K Okumura, H Yagita.   

Abstract

BACKGROUND & AIMS: Fas has been implicated in liver damage. The aim of this study was to investigate the role of its ligand to induce hepatocyte death and liver damage in T cell-dependent hepatitis.
METHODS: Fas ligand-mediated lysis of primary hepatocytes from C57BL/6 wild-type, Fas ligand-deficient gld, and Fas-deficient lpr mice and concanavalin A-induced hepatitis in these mice were assessed.
RESULTS: Freshly isolated hepatocytes from wild-type or gld mice, but not those from lpr mice, were susceptible to Fas ligand-mediated lysis. When concanavalin A was intravenously administered into wild-type mice, they developed acute hepatic injury with massive degenerative changes in hepatocytes. In contrast, both gld and lpr mice had lower aminotransferase levels with milder histological changes. Reverse-transcription polymerase chain reaction and flow cytometric analysis showed that Fas ligand was induced in the liver shortly after the concanavalin A injection and was predominantly expressed on intrahepatic T cells. Administration of monoclonal antibody neutralizing mouse Fas ligand could reduce the aminotransferase increase.
CONCLUSIONS: The results indicate that Fas ligand plays a role in the T cell-dependent hepatitis induced by concanavalin A administration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322527     DOI: 10.1053/gast.1997.v113.pm9322527

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  43 in total

Review 1.  Animal models of acute hepatic failure.

Authors:  T M Rahman; H J Hodgson
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

Review 2.  Death receptor signaling and autoimmunity.

Authors:  Richard M Siegel; Jagan Muppidi; Margaret Roberts; Melissa Porter; Zhengqi Wu
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Ceramide-rich platforms in transmembrane signaling.

Authors:  Branka Stancevic; Richard Kolesnick
Journal:  FEBS Lett       Date:  2010-02-20       Impact factor: 4.124

4.  Interferon-alpha (IFN-alpha) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway.

Authors:  A Kaser; B Enrich; O Ludwiczek; W Vogel; H Tilg
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

5.  Protection against Fas-mediated and tumor necrosis factor receptor 1-mediated liver injury by blockade of FADD without loss of nuclear factor-kappaB activation.

Authors:  K Seino; Y Setoguchi; T Ogino; N Kayagaki; H Akiba; H Nakano; H Taniguchi; Y Takada; K Yuzawa; T Todoroki; Y Fukuchi; H Yagita; K Okumura; K Fukao
Journal:  Ann Surg       Date:  2001-11       Impact factor: 12.969

6.  Crucial Fas-Fas ligand interaction in spontaneous acceptance of hepatic allografts in mice.

Authors:  Hideaki Uchiyama; Kenji Kishihara; Ryosuke Minagawa; Koji Hashimoto; Keizo Sugimachi; Kikuo Nomoto
Journal:  Immunology       Date:  2002-04       Impact factor: 7.397

7.  2,3,7,8-TCDD enhances the sensitivity of mice to concanavalin A immune-mediated liver injury.

Authors:  Aaron M Fullerton; Robert A Roth; Patricia E Ganey
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-16       Impact factor: 4.219

8.  Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Authors:  Akihiro Hasegawa; Xin Cheng; Kiichi Kajino; Alan Berezov; Kaoru Murata; Toshinori Nakayama; Hideo Yagita; Ramachandran Murali; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

9.  Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma.

Authors:  Azza E I El Bassiouny; Nora E I El-Bassiouni; Mona M F Nosseir; Mona M K Zoheiry; Eman G El-Ahwany; Faten Salah; Zeinab S O Omran; Raafat A Ibrahim
Journal:  Medscape J Med       Date:  2008-06-03

10.  Contribution of gut bacteria to liver pathobiology.

Authors:  Gakuhei Son; Michael Kremer; Ian N Hines
Journal:  Gastroenterol Res Pract       Date:  2010-07-28       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.